There is currently a shortage of both strengths of Bicillin L-A (benzathine benzylpenicillin tetrahydrate) prefilled syringes for injection (600,000 units per syringe and 1.2 million units per syringe). The shortage is expected to last until 30 November 2026. Refer to the TGA website for updates on an expected resolution date. Bicillin L-A 1.2 million unit prefilled syringe for injection is now limited to emergency supply only. Healthcare professionals can contact Pfizer Australia directly on 1800 675 229 for ordering information. The TGA have approved overseas-registered benzathine benzylpenicillin products until 31 January 2027 under section 19A of the Therapeutic Goods Act 1989. For advice on treating non-pregnant people with suspect or proven syphilis, and their sexual contacts, with doxycycline refer to Special Treatment Situation.


| 14 May 2026 |

Syphilis

Overview

  • Continuing high prevalence in men who have sex with men and remote Aboriginal and Torres Strait Islander communities, and increasing prevalence in major cities.
  • Recent concerning increase in prevalence in the general population, especially in women of reproductive age, so low threshold for testing is required.
  • Syphilis in pregnant people has led to the re-emergence of congenital syphilis. If diagnosed during pregnancy, seek urgent specialist advice and ensure urgent and active recall for treatment.
  • There are multiple ongoing outbreaks across Australia, especially in Aboriginal and Torres Strait Islander communities in remote areas.
  • Syphilis registries can provide information and support in some states and territories.